Opinion
Video
Author(s):
Panelists discuss the initial approach to the management of RET-positive non–small cell lung cancer (NSCLC), focusing on treatment strategies and the role of targeted therapies such as RET inhibitors in first-line treatment.
Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer
Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL